Form 4: Syndax Director Keith Katkin Awarded 24,000 RSUs

Syndax Pharmaceuticals Director Keith Katkin received an award of 24,000 Restricted Stock Units, increasing his direct beneficial ownership to 124,000 shares.

Summary

• Keith Katkin, a Director of Syndax Pharmaceuticals Inc (SNDX), was awarded 24,000 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was February 4, 2026.
• The RSUs were acquired at a price of $0, indicating an equity award rather than a purchase.
• Following this transaction, Mr. Katkin's direct beneficial ownership of Syndax Pharmaceuticals Common Stock increased to 124,000 shares.
• The Restricted Stock Units vest one year from the date of grant.
• The shares underlying these RSUs will not be delivered to Mr. Katkin and cannot be transferred or sold until the earlier of a separation from service, death, disability, or a change in control.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive, routine event. It signifies continued alignment of a director's interests with shareholders through equity compensation, which is generally well-received, but it does not represent a new operational or financial development.

Positives

• The award of 24,000 Restricted Stock Units to Director Keith Katkin aligns his interests further with those of shareholders, as his compensation is tied to the company's future performance.
• An increase in direct beneficial ownership to 124,000 shares demonstrates continued commitment from a key board member.

Future Outlook

The Restricted Stock Units are scheduled to vest one year from the grant date, indicating a future increase in the director's vested equity holdings, contingent on continued service or specific triggering events.

Industry Context

StockSavvy.ai notes that the award of Restricted Stock Units to a director is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of executive and board compensation packages designed to align leadership incentives with long-term shareholder value.

Comparison to Industry Standards

• StockSavvy.ai notes that RSU awards are a standard form of equity compensation for directors across the biotech and broader public company landscape, aligning with typical corporate governance structures.
• The vesting schedule of one year is also a common practice for such awards, promoting retention and long-term commitment.

Stakeholder Impact

• Shareholders: Increased alignment of Director Keith Katkin's interests with long-term shareholder value due to equity-based compensation.
• Employees: No direct impact mentioned, but such awards are part of a broader compensation philosophy.

Next Steps

• The Restricted Stock Units are expected to vest one year from the grant date (February 4, 2027).
• Shares underlying the RSUs will be delivered upon the earlier of separation from service, death, disability, or a change in control.

Key Dates

Recommendation

The award of Restricted Stock Units to a director is a routine compensation event and does not provide new fundamental information to warrant a change in investment recommendation. Investors should continue to evaluate Syndax Pharmaceuticals based on its operational performance, pipeline developments, and broader market conditions.

Keywords

Syndax Pharmaceuticals, SNDX, Form 4, Restricted Stock Units, RSU, Insider Transaction, Equity Award, Director Compensation